GlassScriptPhysician profile
Steven P Freeman
NPI 1679582506
$2,852.94
in general payments reported to CMS, 2019-2025
28 companies · $751 in 2025
The $751 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $394 · 2021: $85.93 · 2022: $314 · 2023: $352 · 2024: $749 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,852.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $408.62 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $309.71 | 2023-2025 | Camzyos, Eliquis |
| Pfizer INC. | $285.98 | 2022-2025 | |
| Biotronik INC. | $257.58 | 2020-2025 | Selectra, Solia, Amvia Edge |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $251.25 | 2020-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.36 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $152.10 | 2022-2025 | Verquvo, Steglatro, Capvaxive |
| Edwards Lifesciences Corporation | $113.32 | 2019-2021 | |
| Boston Scientific Corporation | $110.96 | 2021-2024 | Watchman Access System, Watchman Flx |
| Janssen Pharmaceuticals, INC | $106.95 | 2021-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $87.73 | 2019-2024 | |
| Abbott Laboratories | $69.81 | 2025 | Cardiomems, Perclose Prostyle |
| Astrazeneca Pharmaceuticals LP | $59.80 | 2024-2025 | |
| Lantheus Medical Imaging, INC. | $56.86 | 2023-2024 | Definity |
| Daiichi Sankyo INC. | $54.71 | 2024 | Injectafer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $54.60 | 2022 | |
| Novartis Pharmaceuticals Corporation | $46.34 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $32.74 | 2025 | Amvuttra |
| Baxter Healthcare | $32.06 | 2024 | Perclot |
| Medtronic Vascular, INC. | $30.51 | 2020 | |
| Atricure, INC. | $30.22 | 2024 | |
| Biosense Webster, INC. | $22.87 | 2024 | Qdot Micro Catheter |
| Bridgebio Pharma, INC. | $21.50 | 2025 | Attruby |
| Penumbra, INC. | $21.30 | 2023 | Indigo System |
| Regeneron Healthcare Solutions, INC. | $21.29 | 2024 | Evkeeza |
| Esperion Therapeutics, INC. | $20.75 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $17.58 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $13.44 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.